Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.41 USD | +2.39% | +0.73% | -9.40% |
Business Summary
Number of employees: 167
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Drug Products
100.0
%
| 214 | 100.0 % | 398 | 100.0 % | +85.90% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 214 | 100.0 % | 398 | 100.0 % | +85.90% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Patrick McEnany
FOU | Founder | 77 | 31/12/01 |
Richard Daly
CEO | Chief Executive Officer | 62 | 18/02/15 |
Michael Kalb
DFI | Director of Finance/CFO | 53 | 12-31 |
Stanley Iyadurai
CTO | Chief Tech/Sci/R&D Officer | - | 19/08/18 |
Brian Elsbernd
CMP | Compliance Officer | 60 | 28/02/16 |
Steven Miller
COO | Chief Operating Officer | 62 | 31/03/07 |
Gary Ingenito
CTO | Chief Tech/Sci/R&D Officer | 68 | 31/05/15 |
Charles O'Keeffe
BRD | Director/Board Member | 84 | 30/11/04 |
Mary Coleman
IRC | Investor Relations Contact | - | 15/08/21 |
Preethi Sundaram
PRN | Corporate Officer/Principal | 47 | 05/07/21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick McEnany
FOU | Founder | 77 | 31/12/01 |
Donald Denkhaus
BRD | Director/Board Member | 78 | 18/02/15 |
David Tierney
BRD | Director/Board Member | 60 | 30/09/02 |
Charles O'Keeffe
BRD | Director/Board Member | 84 | 30/11/04 |
Richard Daly
CEO | Chief Executive Officer | 62 | 18/02/15 |
Molly Harper
BRD | Director/Board Member | 48 | 28/06/21 |
Tamar Thompson
BRD | Director/Board Member | 50 | 24/05/23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 118,011,092 | 110,678,237 ( 93.79 %) | 0 | 93.79 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
1,414,688 | 11.21% | 15,345,290 $ |
Company contact information
Catalyst Pharmaceuticals, Inc.
355 Alhambra Circle Suite 801
33134, Coral Gables
+305 420 3200
http://www.catalystpharma.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.40% | 1.78B | |
-4.24% | 86.85B | |
+2.76% | 40.16B | |
-16.86% | 31.28B | |
+57.86% | 25.27B | |
-14.29% | 15.33B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+6.89% | 8.83B | |
-10.53% | 7.94B |
- Stock Market
- Equities
- CPRX Stock
- Company Catalyst Pharmaceuticals, Inc.